natgillin/translations-raw huggingface dataset:
The European Medicines Agency has deferred the obligation to submit the results of studies with Kevzara (sarilumab) in one or more subsets of the paediatric population in chronic idiopathic arthritis (including rheumatoid arthritis, spondylarthritis, psoriatic arthritis and juvenile idiopathic arthritis) (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom Kevzara (sarilumab) za eno ali več podskupin pediatrične populacije pri kroničnem idiopatičnem artritisu (vključno z revmatoidnim artritisom, spondilartritisom, psoriatičnim artritisom in juvenilnim idiopatičnim artritisom) (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
MOBILITY evaluated 1197 patients with RA who had inadequate clinical response to MTX. 
Študija MOBILITY je ocenila 1197 bolnikov z RA, ki se niso klinično ustrezno odzvali na metotreksat.
Select the injection site. 
Izberite mesto injiciranja.
Elderly: No dose adjustment is required in patients over 65 years of age (see section 4.4). 
Starejše osebe: Bolnikom, starejšim od 65 let, odmerka ni treba prilagoditi (glejte poglavje 4.4).
Blood and Lymphatic System Disorders 
Bolezni krvi in limfatičnega sistema
Treatment should be started by a doctor experienced in the diagnosis and treatment of rheumatoid arthritis. 
Zdravljenje mora uvesti zdravnik, ki ima izkušnje v diagnosticiranju in zdravljenju revmatoidnega artritisa.
Monoclonal antibodies are not eliminated via renal or hepatic pathways. 
Monoklonska protitelesa se ne odstranijo po ledvični ali jetrni poti.
• inject your missed dose as soon as you can. 
• izpuščeni odmerek injicirajte čim prej.
Current dose of Kevzara should be maintained. 
Trenutni odmerek zdravila Kevzara je treba ohraniti.
Lipid parameters (LDL, HDL, and triglycerides) were first assessed at 4 weeks following initiation of Kevzara+ DMARDs in the placebo-controlled population. 
Lipidi Vrednosti lipidov (LDL, HDL in trigliceridov) so najprej ocenili 4 tedne po uvedbi kombinacije zdravila Kevzara + DMARD v populaciji, kontrolirani s placebom.
• cold sores (“oral herpes”) 
• oralni herpes ("ocvirki")
There are no or limited amount of data from the use of sarilumab in pregnant women. 
Podatkov o uporabi sarilumaba pri nosečnicah ni oziroma so omejeni.
Patients receiving Kevzara 200 mg + DMARDs reported greater improvement relative to placebo in the domains of Physical Functioning, Role Physical, Bodily Pain, General Health Perception, Vitality, Social Functioning, and Mental Health. 
Bolniki, ki so prejemali 200 mg zdravila Kevzara + DMARD, so v primerjavi s placebom navajali večje izboljšanje na področjih telesnega delovanja, telesne vloge, telesnih bolečin, splošnega dojemanja zdravja, vitalnosti, socialnega delovanja in mentalnega zdravja.
Sanofi Winthrop Industrie 1051 Boulevard Industriel 76580 Le Trait, France 
Sanofi Winthrop Industrie 1051 Boulevard Industriel 76580 Le Trait, Francija
Figure 1: Percent of ACR20 Response by Visit for MOBILITY 
Slika 1: Odstotek odziva ACR20 po obisku v študiji MOBILITY
The total content (1.14 ml) of the pre-filled syringe/pre-filled pen should be administered as a subcutaneous injection. 
Celotno vsebino (1,14 ml) napolnjene injekcijske brizge/napolnjenega injekcijskega peresnika je treba uporabiti v subkutani injekciji.
After removing the pre-filled syringe/pre-filled pen from the refrigerator, it should be allowed to reach room temperature (<25°C) before injecting Kevzara. 
Potem, ko vzamemo napolnjena injekcijska brizga/napolnjen injekcijski peresnik iz hladilnika, je treba pustiti da pred injiciranjem zdravila Kevzara doseže sobno temperaturo (< 25 °C).
When considering anti-tuberculosis therapy, consultation with a physician with expertise in tuberculosis may be appropriate. 
Kadar razmišljate o protituberkuloznem zdravljenju, premislite o posvetu z zdravnikom, ki ima izkušnje na področju tuberkuloze.
TARGET evaluated 546 patients with RA who had an inadequate clinical response or were intolerant to one or more TNF-α antagonists. 
Študija TARGET je ocenila 546 bolnikov z RA, ki se niso ustrezno klinično odzvali na enega ali več antagonistov TNF-α ali teh zdravil niso prenašali.
Twist or pull off the orange cap. 
Zavrtite ali snemite oranžen pokrovček.
Cases of opportunistic infection have been reported (see section 4.4). 
Poročali so o primerih oportunističnih okužb (glejte poglavje 4.4).
The symptoms may include fever, sweats, or chills. 
Med simptomi so lahko zvišana telesna temperatura, znojenje ali mrzlica.
IL-6 is involved in diverse physiological processes such as migration and activation of T-cells, B-cells, monocytes, and osteoclasts leading to systemic inflammation, synovial inflammation, and bone erosion in patients with RA. 
IL-6 je vpleten v različna fiziološka dogajanja, npr. migracijo in aktivacijo celic T, celic B, monocitov in osteoklastov, in povzroča sistemsko vnetje, vnetje sinovije in erozijo kosti pri bolnikih z RA.
• you have recently had any vaccination or are going to have a vaccination. 
• ste nedavno opravili kakšno cepljenje ali imate predvideno kakšno cepljenje.
After multiple dosing of 150 to 200 mg every two weeks, steady state was reached in 12 to 16 weeks with a 2- to 3-fold accumulation compared to single dose exposure. 
Po večkratnem odmerjanju od 150 do 200 mg na dva tedna je bilo stanje dinamičnega ravnovesja doseženo v 12 do 16 tednih z 2- do 3-kratnim kopičenjem v primerjavi z izpostavljenostjo po enkratnem odmerku.
Upon initiation or discontinuation of Kevzara in patients being treated with CYP substrate medicinal products, therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., theophylline) should be performed and the individual dose of the medicinal product should be adjusted as needed. 
Po uvedbi ali prenehanju uporabe zdravila Kevzara pri bolnikih, ki prejemajo zdravila, ki so substrati CYP, je treba spremljati terapevtski učinek (npr. pri varfarinu) ali koncentracije zdravila (npr. teofilina) in individualno prilagoditi odmerek zdravila, kot je potrebno.
Do not inject a double dose to make up for a forgotten injection. 
Ne injicirajte dvojnega odmerka, če ste pozabili injicirati prejšnjega.
If you are using any of the following medicines, tell your doctor or pharmacist before using Kevzara: 
Če uporabljate katero od naslednjih zdravil, o tem obvestite zdravnika ali farmacevta, preden uporabite zdravilo Kevzara:
• a history of serious or opportunistic infections; 
• kronične ali ponavljajoče se okužbe, • anamnezo resnih ali oportunističnih okužb,
Most patients who developed gastrointestinal perforations were taking concomitant nonsteroidal anti-inflammatory medications (NSAIDs), corticosteroids, or methotrexate. 
Večina bolnikov, ki se jim je pojavila perforacija prebavil, so sočasno jemali nesteroidna protivnetna zdravila (NSAR), kortikosteroide ali metotreksat.
In both MOBILITY and TARGET, higher ACR20 response rates were observed within 2 weeks compared to placebo and were maintained for the duration of the studies (see Figures 1 and 2). 
V obeh študijah, MOBILITY in TARGET, so po 2 tednih opažali večji delež odziva ACR20 kot s placebom in to se je ohranilo med celotnim trajanjem študij (glejte sliki 1 in 2).
The interval between live vaccinations and initiation of Kevzara therapy should be in accordance with current vaccination guidelines regarding immunosuppressive agents (see section 4.5). 
Presledek med uporabo živih cepiv in uvedbo zdravila Kevzara mora biti v skladu s trenutnimi smernicami za cepljenja, ki zadevajo imunosupresivna zdravila (glejte poglavje 4.5).
Talk to your doctor, pharmacist, or nurse if: 
Posvetujte se z zdravnikom, farmacevtom ali medicinsko sestro, če:
Consider anti-tuberculosis therapy prior to initiation of Kevzara in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. 
Pred uvedbo zdravila Kevzara razmislite o protituberkuloznem zdravljenju pri bolnikih, ki so imeli v preteklosti latentno ali aktivno tuberkulozo, a pri katerih ni mogoče potrditi ustrezno opravljenega zdravljenja, ter pri bolnikih, ki imajo negativen izvid testiranja za latentno tuberkulozo, vendar imajo dejavnike tveganja za tuberkulozno okužbo.
Contents of the pack and other information What Kevzara contains 
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Kevzara
The MAH shall ensure that in each Member State where Kevzara is marketed, all healthcare professionals who are expected to prescribe Kevzara have access to the patient alert card. 
Imetnik dovoljenja za promet bo zagotovil, da bodo v vseh državah članicah, kjer bo zdravilo Kevzara na trgu, vsi zdravniki, ki bodo predvidoma predpisovali zdravilo Kevzara, imeli dostop do opozorilnih kartic za bolnika.
A patient who develops an infection during treatment with Kevzara should also undergo prompt and complete diagnostic testing appropriate for an immunocompromised patient; appropriate antimicrobial therapy should be initiated, and the patient should be closely monitored. 
Če se bolniku med zdravljenjem z zdravilom Kevzara pojavi okužba, je treba tudi takoj opraviti celotno diagnostično testiranje, primerno za imunsko oslabele bolnike; uvesti je treba ustrezno antimikrobno zdravljenje in bolnika skrbno nadzirati.
Blockade of IL-6 signalling by IL-6Rα antagonists such as sarilumab might reverse the inhibitory effect of IL-6 and restore CYP activity, leading to altered medicinal products concentrations. 
Blokada signalizacije IL-6 z antagonisti IL-6Rα, kakršen je sarilumab, lahko preobrne zaviralni učinek IL-6 in obnovi aktivnost CYP ter tako povzroči spremembo koncentracije zdravil.
• A warning message for HCPs treating the patient at any time, including in conditions of emergency, that the patient is using Kevzara. 
• Opozorilo zdravnikom, ki kadar koli zdravijo bolnika - to velja tudi za primere nujnega zdravljenja - da bolnik uporablja zdravilo Kevzara.
Also some other medicines can affect the way Kevzara works. 
Tudi nekatera druga zdravila lahko vplivajo na delovanje zdravila Kevzara.
The use of Kevzara is not expected to affect your ability to drive or use machines. 
Ni pričakovati, da bi zdravilo Kevzara vplivalo na vašo sposobnost upravljanja vozil ali strojev.
• Hold the syringe in the middle of the syringe body with the needle pointing away from you. 
• Primite brizgo na sredini telesa brizge in tako, da bo igla obrnjena proč od vas.
Treatment with Kevzara was associated with increases in lipid parameters such as LDL cholesterol, HDL cholesterol, and/or triglycerides (see section 4.8). 
Zdravljenje z zdravilom Kevzara je bilo povezano z zvišanjem vrednosti lipidov, na primer holesterola LDL, holesterola HDL in/ali trigliceridov (glejte poglavje 4.8).
• You can inject into your thigh or belly (abdomen) except for the 5 cm around your belly button (navel). 
• Injicirate lahko v stegno ali v trebuh; razen v predel 5 cm okrog popka.
Transaminases increased 
Zvišanje vrednosti transaminaz
In 17 patients with RA, one week following a single 200-mg subcutaneous administration of sarilumab, exposure of simvastatin and simvastatin acid decreased by 45% and 36%, respectively (see section 4.5). 
Pri 17 bolnikih z RA se je en teden po enkratnem 200-mg subkutanem odmerku sarilumaba izpostavljenost simvastatinu zmanjšala za 45 % in izpostavljenost simvastatinski kislini za 36 % (glejte poglavje 4.5).
Low Platelet Count Lab Value (cells x 103/µL) 
Majhno število trombocitov Laboratorijska vrednost (celice x 103/µl)
• Low white blood cell counts shown by blood tests 
• majhno število belih krvnih celic (pokaže se na preiskavi krvi)
Figure 2: Percent of ACR20 Response by Visit for TARGET 
Slika 2: Odstotek odziva ACR20 po obisku v študiji TARGET
DAS28-ESR remission (< 2.6), n (%) 
DAS28-SR remisija (< 2,6), n (%)
DAS28-ESR (primary endpoint) 
DAS28-SR (primarni opazovani dogodek)
The excretion of sarilumab in milk has not been studied in animals (see section 5.3). 
Izločanja sarilumaba v mleko pri živalih niso raziskali (glejte poglavje 5.3).
Results at 52 weeks in MOBILITY were similar to the results at 24 weeks for TARGET. 
Rezultati študije MOBILITY so bili po 52 tednih podobni rezultatom študije TARGET po 24 tednih.
All presentations contain a 1.14 ml solution in a syringe (type 1 glass) equipped with a stainless steel staked needle and an elastomer plunger stopper. 
Vse oblike vsebujejo 1,14 ml raztopine v brizgi (steklo tipa 1), opremljeni z nameščeno iglo iz nerjavnega jekla in elastomernim čepom bata.
Kevzara has no or negligible influence on the ability to drive or operate machinery. 
Zdravilo Kevzara nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Kevzara 200 mg was superior to adalimumab 40 mg in reducing disease activity and improving physical function, with more patients achieving clinical remission over 24 weeks (see Table 6). 
200 mg zdravila Kevzara je bilo superiorno 40 mg adalimumaba pri zmanjšanju aktivnosti bolezni in izboljšanju telesnega delovanja in po 24 tednih je z njim doseglo klinično remisijo več bolnikov (glejte preglednico 6).
• You and your doctor should decide if you should use Kevzara if you are breast-feeding. 
• Skupaj z zdravnikom se morate odločiti, ali naj uporabljate zdravilo Kevzara, ko dojite.
Sarilumab is a human monoclonal antibody selective for the interleukin-6 (IL-6) receptor, produced in Chinese Hamster Ovary cells by recombinant DNA technology. 
Sarilumab je človeško monoklonsko protitelo, selektivno za receptor interlevkina-6 (IL-6), pridobljeno v celicah jajčnika kitajskega hrčka s tehnologijo rekombinantne DNA.
Table 2: Incidence of liver enzyme abnormalities in controlled clinical studies 
Preglednica 2: Pojavnost nenormalnih vrednosti jetrnih encimov v kontroliranih kliničnih študijah
The median tmax after a single subcutaneous dose was observed in 2 to 4 days. 
Mediani tmax po enkratnem subkutanem odmerku je bil dosežen v 2
The pre-filled syringe/pre-filled pen should be inspected before use. 
Napolnjeno injekcijsko brizgo/napolnjeni injekcijski peresnik je treba pred uporabo pregledati.
Push the plunger down. 
Potisnite bat dol.
• abnormal liver function tests 
• nenormalni testi delovanja jeter
s* 
RD*
Caution should be exercised in patients who start Kevzara treatment while on therapy with CYP3A4 substrates (e.g., oral contraceptives or statins), as Kevzara may reverse the inhibitory effect of IL-6 and restore CYP3A4 activity, leading to decreased exposure and activity of CYP3A4 substrate. 
Previdnost je potrebna pri bolnikih, ki začnejo zdravljenje z zdravilom Kevzara med zdravljenjem s substrati CYP3A4 (npr. peroralnimi kontraceptivi ali statini), ker lahko zdravilo Kevzara preobrne zaviralni učinek IL-6 in obnovi aktivnost CYP3A4 ter tako zmanjša izpostavljenost substratu CYP3A4 in njegovo aktivnost (glejte poglavje 5.2).
• injection-site reactions (including redness and itching). 
• reakcije na mestu injiciranja (vključno s pordelostjo in srbenjem).
• Kevzara attaches to another protein called interleukin-6 (IL-6) receptor and blocks its action. 
• Zdravilo Kevzara se veže na drugo beljakovino, imenovano interlevkin-6 (IL-6), in prepreči njeno delovanje.
Other medicines and Kevzara 
Druga zdravila in zdravilo Kevzara
• you have tuberculosis (TB), symptoms of TB (persistent cough, weight loss, listlessness, mild fever), or have been in close contact with someone with TB. 
• imate tuberkulozo (TB), simptome TB (trdovraten kašelj, hujšanje, brezvoljnost, rahlo zvišano telesno temperaturo) ali če ste bili v tesnem stiku s kom, ki ima TB.
If you stop using Kevzara 
Če ste prenehali uporabljati zdravilo Kevzara
These elevations were not associated with clinically relevant increases in direct bilirubin, nor were they associated with clinical evidence of hepatitis or hepatic insufficiency (see section 4.4). 
Ta zvišanja niso bila povezana s klinično pomembnim zvišanjem vrednosti direktnega bilirubina; prav tako niso bila povezana s kliničnimi manifestacijami hepatitisa ali insuficience jeter (glejte poglavje
There is no specific treatment for Kevzara overdose. 
Specifičnega zdravljenja za preveliko odmerjanje zdravila Kevzara ni.
Patients presenting with new onset abdominal symptoms such as persistent pain with fever should be evaluated promptly (see section 4.8). 
Bolnike z novonastalimi trebušnimi simptomi, na primer z dolgotrajnimi bolečinami in zvišano telesno temperaturo, je treba nemudoma oceniti (glejte poglavje 4.8).
Once removed from the refrigerator, Kevzara should be administered within 14 days and should not be stored above 25 ºC. 
Ko je zdravilo Kevzara vzeto iz hladilnika, ga je treba uporabiti v 14 dneh in ga je treba shranjevati na temperaturi do 25 °C.
• Do not take Kevzara if you are pregnant unless your doctor specifically recommends it. 
• Če ste noseči, ne jemljite zdravila Kevzara, razen če vam to izrecno svetuje zdravnik.
Kevzara in combination with methotrexate (MTX) is indicated for the treatment of moderately to severely active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). 
Zdravilo Kevzara je v kombinaciji z metotreksatom (MTX) indicirano za zdravljenje zmerno do zelo aktivnega revmatoidnega artritisa (RA) pri odraslih bolnikih, ki so se neustrezno odzvali ne eno ali več imunomodulirajočih antirevmatičnih zdravil (DMARD - disease modifying antirheumatic drugs) ali takšnih zdravil ne prenesejo.
Reduction in platelets was not associated with bleeding events (see section 4.8). 
Zmanjšanje števila trombocitov ni bilo povezano s krvavitvami (glejte poglavje 4.8).
Keep the carton in an insulated bag with an ice pack when travelling. 
Ko potujete, imejte škatlo shranjeno v izolirani vrečki z ledenim vložkom.
Ask your doctor, pharmacist or nurse how to throw away the container. 
Zdravnika, farmacevta ali medicinsko sestro vprašajte, kako zavreči vsebnik.
Clinically appropriate dose modification of concomitant DMARDs should be considered. 
Razmisliti je treba o klinično ustrezni prilagoditvi sočasno uporabljanih
No data are available on the effect of sarilumab on human fertility. 
Podatkov o vplivu sarilumaba na plodnost pri človeku ni.
Kevzara is used to treat adults with moderately to severely active rheumatoid arthritis if previous therapy did not work well enough or was not tolerated. 
Zdravilo Kevzara uporabljamo za zdravljenje odraslih z zmerno do zelo aktivnim revmatoidnim artritisom, če pred tem uporabljena zdravila niso dovolj dobro delovala ali jih niso prenesli.
In isolated cases, disseminated rather than localised infections were observed in patients often taking concomitant immunosuppressants such as MTX or corticosteroids, which in addition to RA may predispose them to infections. 
posameznih primerih so opažali diseminirane (ne lokalizirane) okužbe pri bolnikih, ki so pogosto sočasno uporabljali imunosupresive, npr. metotreksat ali kortikosteroide, ki lahko poleg RA povečujejo nagnjenost k okužbam.
p-value versus adalimumab *Includes patients who increased the frequency of dosing of adalimumab 40 mg to every week because of an inadequate response 
*Vključuje bolnike, ki so zaradi neustreznega odziva pogostnost uporabe 40 mg adalimumaba povečali na vsak teden.
Kevzara can then be resumed at 150 mg every 2 weeks and increased to 200 mg every 2 weeks as clinically appropriate. 
Zdravilo Kevzara je mogoče znova začeti uporabljati v odmerku 150 mg na 2 tedna in odmerek povečati na 200 mg na 2 tedna, kot je klinično primerno.
At steady state, exposure over the dosing interval measured by AUC increased approximately 2fold with a 1.33-fold increase in dose from 150 to 200 mg every two weeks. 
V stanju dinamičnega ravnovesja se je izpostavljenost v odmernem intervalu, merjena z AUC, povečala približno 2-krat ob 1,33-kratnem povečanju odmerka s 150 mg na 200 mg na 2
Radiographs of hands and feet were obtained at baseline, 24 weeks, and 52 weeks and scored independently by at least two well-trained readers who were blinded to treatment group and visit number. 
Rentgenske posnetke dlani in stopal so naredili na začetku študije, 24. teden in 52. teden; posnetke sta neodvisno ocenila vsaj dva dobro usposobljena pregledovalca, ki nista bila seznanjena s terapevtsko skupino in številom obiskov.
Kevzara should not be administered in patients with an active infection, including localised infections. 
Zdravila Kevzara se ne sme dajati bolnikom, ki imajo aktivno okužbo; to velja tudi za lokalizirane okužbe.
Before you use Kevzara, your doctor will do a blood test to check your liver function. 
Preden boste uporabili zdravilo Kevzara, bo zdravnik opravil preiskave krvi, da bo preveril delovanje jeter.
• The other ingredients are arginine, histidine, polysorbate 20, sucrose, and water for injections. 
• Druge sestavine so arginin, histidin, polisorbat 20, saharoza in voda za injekcije.
In a usability study sarilumab exposure after 200 mg Q2W was slightly higher (Cmax + 24-34%, AUC(0-2w) +7-21%) after use of a pre-filled pen compared to the pre-filled syringe. 
V študiji uporabnosti je bila izpostavljenost sarilumabu po 200 mg na 2 tedna nekoliko večja (Cmax + 24-34 %, AUC(0-2t) +7-21 %) z uporabo napolnjenega injekcijskega peresnika kot z uporabo napolnjene injekcijske brizge.
The absolute bioavailability for sarilumab after SC injection was estimated to be 80% by population PK analysis. 
Na podlagi populacijske farmakokinetične analize je ocenjena absolutna biološka uporabnost sarilumaba po s.c. injiciranju 80 %.
Reports of gastrointestinal perforation were primarily reported as complications of diverticulitis including lower GI perforation and abscess. 
O perforacijah prebavil so poročali predvsem kot o zapletu divertikulitisa, vključno s perforacijo v spodnjih prebavilih in z abscesi.
Before you are given Kevzara, your doctor will check you for TB. 
Preden boste dobili zdravilo Kevzara, vas bo zdravnik testiral glede TB.
• Contact details of the prescriber for Kevzara. 
• Kontaktne podatke zdravnika, ki je predpisal zdravilo Kevzara.
Patients treated with Kevzara should be given the patient alert card. 
Bolniki, zdravljeni z zdravilom Kevzara, morajo dobiti opozorilno kartico bolnika.
MTX exposure is not expected to be changed by sarilumab coadministration; however, no clinical data was collected. 
Ni pričakovati, da bi sočasna uporaba sarilumaba spremenila izpostavljenost metotreksatu, vendar pa o tem ni nobenih kliničnih podatkov.
• underlying conditions that may predispose them to infection; 
• neko osnovno bolezen, ki lahko poveča nagnjenost k okužbam,
Keep holding the pen firmly against your skin. 
Peresnik še naprej držite trdno ob kožo.
Excipients: histidine, arginine, polysorbate 20, sucrose, water for injections. 
Pomožne snovi: histidin, arginin, polisorbat 20, saharoza, voda za injekcije.
Treatment with Kevzara + MTX was associated with significantly less radiographic progression of structural damage as compared with placebo. 
Zdravljenje z zdravilom Kevzara + metotreksatom je bilo povezano z značilno manjšim rentgenografskim napredovanjem strukturne okvare kot uporaba placeba.
The weight of evidence for IL-6Rα inhibition mainly indicates anti-tumour effects mediated by multiple mechanisms predominantly involving STAT-3 inhibition. 
Zbrani dokazi o zavrtju IL-6Rα kažejo predvsem protitumorske učinke, ki jih posreduje več mehanizmov, predvsem preko zavrtja STAT-3.
• Use the pre-filled syringe exactly as described in the “Instructions for Use”. 
• Napolnjen injekcijski peresnik uporabite natančno tako, kot je opisano v "Navodilih za uporabo".
Kevzara should not be injected into skin that is tender, damaged, or has bruises or scars. 
Zdravila Kevzara se ne sme injicirati v kožo, ki je občutljiva, poškodovana, ima podplutbe ali brazgotine.
The safety and efficacy of Kevzara in children up to 18 years of age have not been established. 
Pediatrična populacija: Varnost in učinkovitost zdravila Kevzara nista ugotovljeni pri otrocih do 18. leta starosti.